Fredun Pharma H1 FY27 Profit Soars 94% to ₹31.99 Cr

Fredun Pharmaceuticals Limited announced its unaudited financial results for H1 FY27, reporting a significant surge in performance. Net profit soared by 93.92% to ₹31.99 Cr (₹16.50 Cr in H1 FY26), while EBITDA rocketed by 91.67% to ₹75.38 Cr (₹39.33 Cr in H1 FY26). Total income surged by 87.02% to ₹495.88 Cr (₹265.15 Cr in H1 FY26). The company also highlighted strategic business developments, including a 26% stake acquisition in Goodman Vetcare for ₹300 crore and the acquisition of the pet-wellness brand Furlicks. Fredun Pharmaceuticals is expanding manufacturing capacity and widening its product basket, aiming for sustainable, profitable growth.